CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013	Mar. 31, 2012
Revenues:
Research and development support	$ 2,257	$ 1,320	$ 5,670	$ 3,333
License and milestone fees	22,010	999	23,372	8,211
Clinical materials revenue	734	933	2,662	1,861
Total revenues	25,001	3,252	31,704	13,405
Operating Expenses:
Research and development	21,318	16,933	66,674	49,653
General and administrative	4,995	5,021	16,098	14,696
Total operating expenses	26,313	21,954	82,772	64,349
Loss from operations	(1,312)	(18,702)	(51,068)	(50,944)
Other (expense) income, net	(39)	33	132	39
Net loss	(1,351)	(18,669)	(50,936)	(50,905)
Basic and diluted net loss per common share (in dollars per share)	$ (0.02)	$ (0.24)	$ (0.61)	$ (0.66)
Basic and diluted weighted average common shares outstanding (in shares)	84,279	76,961	83,923	76,615
Comprehensive loss	$ (1,351)	$ (18,669)	$ (50,936)	$ (50,905)